

## Announced insider trading

Emil Billbäck, CEO, has sold 62 927 shares to cover tax effects of shares distributed in Long Term Incentive Program 2024. After the transaction, he owns 536 171 shares, which is 81 746 shares more than at the onset of 2024.

Håkan Johansson, CFO, has sold 22 000 shares to cover tax effects of shares distributed in Long Term Incentive Program 2024. After the transaction, he owns 74 000 shares, which is 19 000 shares more than at the onset of 2024.

### For more information contact:

---

BONESUPPORT AB  
Emil Billbäck, CEO  
+46 (0) 46 286 53 70

Håkan Johansson, CFO  
+46 (0) 46 286 53 70  
[ir@bonesupport.com](mailto:ir@bonesupport.com)

Cord Communications  
Charlotte Stjerngren  
+46 (0) 708 76 87 87  
[charlotte.stjerngren@cordcom.se](mailto:charlotte.stjerngren@cordcom.se)  
[www.cordcom.se](http://www.cordcom.se)

### About BONESUPPORT™

---

BONESUPPORT (Nasdaq Stockholm: BONEX) develops and commercializes innovative injectable bio-ceramic bone graft substitutes that remodel to the patient's own bone and have the capability of eluting drugs. BONESUPPORT's bone graft substitutes are based on the patented technology platform **CERAMENT**. The company is conducting several clinical studies to further demonstrate the clinical and health economic benefits its products deliver. The company is based in Lund, Sweden, and the net sales amounted to SEK 591 million in 2023. Please visit [www.bonesupport.com](http://www.bonesupport.com) for more information.

BONESUPPORT and CERAMENT are **registered trademarks** of BONESUPPORT AB.

### Attachments

---

### [Announced insider trading](#)